Pat B Zanzonico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5905467/publications.pdf

Version: 2024-02-01

66 papers

4,163 citations

30 h-index 63 g-index

70 all docs

70 docs citations

times ranked

70

6651 citing authors

#	Article	IF	Citations
1	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Molecular Cancer Therapeutics, 2022, 21, 125-137.	4.1	5
2	F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation. Journal of Nuclear Cardiology, 2022, 29, 3179-3188.	2.1	7
3	Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma. Clinical Cancer Research, 2022, 28, 2938-2952.	7. 0	11
4	A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clinical Cancer Research, 2021, 27, 532-541.	7.0	19
5	IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab—pharmacokinetic modeling to optimize therapeutic index. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1166-1177.	6.4	9
6	Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2021, 109, 905-912.	0.8	13
7	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. Clinical Cancer Research, 2021, 27, 2050-2060.	7.0	13
8	Use of Ultrasmall Core-Shell Fluorescent Silica Nanoparticles for Image-Guided Sentinel Lymph Node Biopsy in Head and Neck Melanoma. JAMA Network Open, 2021, 4, e211936.	5.9	59
9	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nature Communications, 2021, 12, 4669.	12.8	19
10	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 12S-22S.	5.0	14
11	18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1446-1457.	6.4	13
12	An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjugate Chemistry, 2020, 31, 501-506.	3.6	16
13	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. Journal of Clinical Oncology, 2020, 38, 4283-4291.	1.6	40
14	Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model. Clinical Cancer Research, 2020, 26, 147-158.	7.0	59
15	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. Journal of Nuclear Medicine, 2020, 61, 1580-1587.	5.0	5
16	Hybrid PET/MRI enables high-spatial resolution, quantitative imaging of amyloid plaques in an Alzheimer's disease mouse model. Scientific Reports, 2020, 10, 10379.	3.3	15
17	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with $\hat{l}\pm$ Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 459-473.	1.0	13
18	Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled $\hat{l}\pm$ -melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. Biomaterials, 2020, 241, 119858.	11.4	35

#	Article	IF	CITATIONS
19	Patient-adapted organ absorbed dose and effective dose estimates in pediatric 18F-FDG positron emission tomography/computed tomography studies. BMC Medical Imaging, 2020, 20, 9.	2.7	10
20	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell, 2019, 36, 559-573.e7.	16.8	40
21	PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms. Journal of Nuclear Medicine, 2019, 60, 1802-1811.	5.0	27
22	Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. Journal of Neuro-Oncology, 2019, 143, 101-106.	2.9	17
23	A Critical Assessment of the Linear No-Threshold Hypothesis. Clinical Nuclear Medicine, 2019, 44, 521-525.	1.3	23
24	Molecular phenotyping and image-guided surgical treatment of melanoma using spectrally distinct ultrasmall core-shell silica nanoparticles. Science Advances, 2019, 5, eaax5208.	10.3	36
25	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸ F-(2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine. Radiology, 2018, 287, 667-675.	7.3	80
26	Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ⟨sup⟩18⟨ sup⟩Fâ€⟨scp⟩FDG⟨ scp⟩ injection. Medical Physics, 2018, 45, 2179-2185.	3.0	8
27	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹ Zr-Trastuzumab in Patients with Esophagogastric Cancer. Journal of Nuclear Medicine, 2018, 59, 161-166.	5.0	96
28	Biodistribution and Dosimetry of ¹⁸ F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. Journal of Nuclear Medicine, 2018, 59, 147-153.	5.0	96
29	Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging. ACS Applied Materials & Samp; Interfaces, 2018, 10, 4379-4393.	8.0	40
30	First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using ⁸⁹ Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. Journal of Nuclear Medicine, 2018, 59, 900-906.	5.0	126
31	Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma. Theranostics, 2018, 8, 5106-5125.	10.0	32
32	Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nature Communications, 2018, 9, 4141.	12.8	126
33	Guest Editorial. Seminars in Nuclear Medicine, 2018, 48, 309-310.	4.6	1
34	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncology, The, 2018, 19, 1040-1050.	10.7	201
35	Establishment of the <i>In Vivo</i> Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. Molecular Cancer Therapeutics, 2017, 16, 124-133.	4.1	79
36	Pharmacokinetic Analysis of Dynamic ¹⁸ F-Fluoromisonidazole PET Data in Non–Small Cell Lung Cancer. Journal of Nuclear Medicine, 2017, 58, 911-919.	5.0	22

3

#	Article	IF	CITATIONS
37	Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations. Chemistry of Materials, 2017, 29, 8766-8779.	6.7	58
38	Target-or-Clear Zirconium-89 Labeled Silica Nanoparticles for Enhanced Cancer-Directed Uptake in Melanoma: A Comparison of Radiolabeling Strategies. Chemistry of Materials, 2017, 29, 8269-8281.	6.7	59
39	Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 1735-1742.	5.0	36
40	Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016, 8, 535-553.	6.1	49
41	Radiosynthesis of the iodineâ€124 labeled Hsp90 inhibitor PUâ€H71. Journal of Labelled Compounds and Radiopharmaceuticals, 2016, 59, 129-132.	1.0	17
42	Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nature Nanotechnology, 2016, 11, 977-985.	31.5	467
43	The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature, 2016, 538, 397-401.	27.8	233
44	Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Research, 2016, 6, 79.	2.5	25
45	Arsenic Trioxide as a Radiation Sensitizer for ¹³¹ I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of Nuclear Medicine, 2016, 57, 231-237.	5.0	17
46	Adaptation, Commissioning, and Evaluation of a 3D Treatment Planning System for High-Resolution Small-Animal Irradiation. Technology in Cancer Research and Treatment, 2016, 15, 460-471.	1.9	6
47	Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 925-937.	6.4	38
48	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Research, 2016, 6, 7.	2.5	32
49	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. Journal of Nuclear Medicine, 2016, 57, 334-341.	5.0	16
50	Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰ Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Journal of Nuclear Medicine, 2015, 56, 805-811.	5.0	39
51	Gene therapy using therapeutic andÂdiagnostic recombinant oncolytic vaccinia virus GLV-1h153 forÂmanagement of colorectal peritoneal carcinomatosis. Surgery, 2015, 157, 331-337.	1.9	11
52	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1700-1706.	6.4	13
53	Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. International Journal of Radiation Oncology Biology Physics, 2015, 93, 444-453.	0.8	12
54	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Science Translational Medicine, 2014, 6, 260ra149.	12.4	589

#	Article	IF	CITATIONS
55	The potential of theragnostic 124I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. Neuro-Oncology, 2014, 16, 800-806.	1.2	38
56	Principles of Nuclear Medicine Imaging: Planar, SPECT, PET, Multi-modality, and Autoradiography Systems. Radiation Research, 2012, 177, 349-364.	1.5	79
57	Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. Journal of Clinical Investigation, 2011, 121, 2768-2780.	8.2	558
58	Routine Quality Control of Clinical Nuclear Medicine Instrumentation: A Brief Review. Journal of Nuclear Medicine, 2008, 49, 1114-1131.	5.0	141
59	Patient-Specific Radiation Dosimetry for Radionuclide Therapy of Liver Tumors With Intrahepatic Artery Rhenium-188 Lipiodol. Seminars in Nuclear Medicine, 2008, 38, S30-S39.	4.6	10
60	Radiation Exposure of Computed Tomography and Direct Intracoronary Angiography. Journal of the American College of Cardiology, 2006, 47, 1846-1849.	2.8	79
61	Introduction to Clinical and Laboratory (Small-Animal) Image Registration and Fusion. , 2006, 2006, 1580-3.		11
62	Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nuclear Medicine and Biology, 2006, 33, 65-70.	0.6	34
63	PET-Based Biological Imaging for Radiation Therapy Treatment Planning. Critical Reviews in Eukaryotic Gene Expression, 2006, 16 , 61 - 102 .	0.9	15
64	[1311]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 988-997.	6.4	36
65	Broad-Spectrum Multi-Modality Image Registration: From PET, CT, and MRI to Autoradiography, Microscopy, and Beyond., 2006, 2006, 1584-8.		11
66	Broad-Spectrum Multi-Modality Image Registration: From PET, CT, and MRI to Autoradiography, Microscopy, and Beyond. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0